1 research outputs found
Molecular Profiling of Pooled Circulating Tumor Cells from Prostate Cancer Patients Using a Dual-Antibody-Functionalized Microfluidic Device
To
capture both epithelial and mesenchymal subpopulations of CTCs
at different metastatic stages of PCa patients, here we constructed
a novel dual-antibody-functionalized microfluidic device by employing
antibodies against PSMA and EpCAM. In vitro experiments with the dual
capture system for capturing both LnCAP and LnCAP-EMT cells have shown
significantly enhanced capture efficiency as compared to that of the
EpCAM single capture system. Furthermore, the dual capture system
could successfully identify CTCs in 20 out of 24 (83.3%) PCa patients,
and the CTCs counts from the dual capture system were statistically
correlated with the TNM stage of patients (<i>P</i> <
0.05), while conventional diagnostic methods, such as serum PSA level
and Gleason score, failed to correlate to patient TNM stages. To further
explore potential clinical application of our dual capture system,
captured CTCs were recovered and subjected to qRT-PCR to quantify
known factors involved in PCa development and therapy. The results
demonstrated that the combined detection of SChLAP1 and PSA in CTCs
is a potential marker for identifying patients with metastatic PCa,
while detection of AR and PD-L1 in CTCs may have the potential to
determine the sensitivity of PCa patients to androgen deprivation
therapy and immunotherapy, respectively. Taken together, the dual-antibody-functionalized
microfluidic device established in our study overcomes the limitations
of some CTC capture platforms that only detect epithelial or mesenchymal
CTCs in PCa patients, and detection of the PCa-related RNA signatures
from purified CTCs holds great promise to offer warnings for early
metastasis of PCa and may provide guidance for therapy decisions